Ohio joins Indiana and Kentucky in funding Pear Therapeutics’ digital addiction treatments

By SharpBrains | April 26, 2021

Ohio is third state to fund Pear’s dig­i­tal ther­a­peu­tics to tack­le addic­tion (phar­mafo­rum): The com­pa­ny has been push­ing for more reim­burse­ment of its three mar­ket­ed DTx prod­ucts in the US fol­low­ing a first FDA approval in 2017. Pear said that the Ohio Depart­ment of Men­tal Health and Addic­tion Ser­vices (OhioMHAS) and Recov­ery­Ohio are pro­vid­ing access to…

Read More

From digital therapeutics to personalized mental health solutions: Pear Therapeutics expands platform via partnerships with Empatica, etectRx, KeyWise, and Winterlight

By SharpBrains | April 7, 2021

Pear Ther­a­peu­tics Expands Plat­form with Dig­i­tal Bio­mark­ers, Machine Learn­ing Algo­rithms and Sen­­sor-Based Tech­nolo­gies (press release): Pear Ther­a­peu­tics, Inc. announced today that it has entered into agree­ments with mul­ti­ple tech­nol­o­gy com­pa­nies, includ­ing Empat­i­ca Inc., etec­tRx, Inc., and Key­Wise, Inc. The new tech­nolo­gies com­ple­ment the voice-based bio­mark­ers pre­vi­ous­ly licensed from Win­terlight Labs. These new agree­ments bol­ster Pear’s…

Read More

Happify Health raises $73M to deepen partnerships with pharmaceutical companies and insurance payers

By SharpBrains | March 17, 2021

Hap­pi­fy Health rais­es $73M to expand its dig­i­tal ther­a­peu­tic care deliv­ery capa­bil­i­ties (Mobi­Health News): Found­ed in 2012, Hap­pi­fy is best known for dig­i­tal pro­grams that pro­vid­ed auto­mat­ed self-guid­ed sup­port across var­i­ous areas of men­tal health and well­ness, such as stress man­age­ment for employ­ees or health plan mem­bers. Should the user need addi­tion­al sup­port, the platform…

Read More

The landscape of digital mental health apps: huge unmet needs, quality concerns, app stores asked to ensure transparency

By SharpBrains | February 5, 2021

Address­ing the men­tal health cri­sis (Phar­ma Field): Each day we find out more about the men­tal health effects of the pan­dem­ic. Ear­ly on, the Office for Nation­al Sta­tis­tics found that one in five Britons report­ed symp­toms of depres­sion, com­pared with one in 10 before. And, accord­ing to a recent study led by the Uni­ver­si­ty of Nottingham…

Read More

Neurostimulation device GammaSense by Cognito Therapeutics secures FDA Breakthrough Device Designation to explore Alzheimer’s Disease applications

By SharpBrains | January 14, 2021

Cog­ni­to Ther­a­peu­tics nets FDA break­through label for light, sound ther­a­py for Alzheimer’s dis­ease (Fierce Biotech): Using spe­cif­ic fre­quen­cies of flash­ing lights and sounds to stim­u­late the brain’s elec­tri­cal activ­i­ty, Cog­ni­to Ther­a­peu­tics believes it can help treat Alzheimer’s dis­ease by ener­giz­ing neu­rons and reac­ti­vat­ing the immune system.

Read More

Update: Understanding Brain Health via Cosmological Health, and vice versa

By SharpBrains | December 29, 2020

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing fas­ci­nat­ing find­ings, books and resources for life­long brain health. #1. “The human brain (sec­tion; left image above) func­tions thanks to its wide neu­ronal net­work that is deemed to con­tain approx­i­mate­ly 69 bil­lion neu­rons. On the oth­er hand, the observ­able uni­verse (sec­tion sim­u­la­tion; right image) can count…

Read More